ChristianMatthewCapitiniMD

Pediatric Hematology & Oncology • Madison, WI

Pediatric Hematologic Oncology

Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health

Join to view full profile

Dr. Capitini is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Capitini's full profile

Already have an account?

Office
1111 Highland Ave
WIMR 4137
Madison, WI 53705
Phone+1 608-262-2415

Education & Training

National Cancer InstitutePost-Doctoral Fellowship, 2008 - 2011
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2005 - 2008
National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of MinnesotaResidency, Pediatrics, 2002 - 2005
University of Rochester School of Medicine and DentistryClass of 2002
Drew UniversityBA, Biology, Magna Cum Laude, 1994 - 1998

Certifications & Licensure

WI State Medical License 2011 - 2025
MD State Medical License 2005 - 2012
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2014 Aug 14
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2015 Apr 08
Completed
Phase 2
CAR-T Long Term Follow Up (LTFU) Study Start of enrollment: 2015 Nov 02
Recruiting
Phase 3
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients Start of enrollment: 2019 Feb 15
Completed
Phase 2
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Start of enrollment: 2019 Jun 24
Recruiting
Phase 2
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors Start of enrollment: 2016 Feb 12
Recruiting
Phase 1
SPEARHEAD-3 Pediatric Study Start of enrollment: 2023 Sep 01
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
Jonathan D Bender, Sudarshawn Damodharan, Christian M Capitini, Amy Moskop, Keri Toner
Blood Advances. 2024-08-13
3 citations
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams
Nature Cancer. 2024-08-01
TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant.
Aicha Quamine, Nicholas R Mohrdieck, Chloe A King, Anastasia A Griggs, Jillian M Kline
Biorxiv. 2024-07-12

Journal Articles

Bioengineering Solutions for Manufacturing Challenges in CAR T Cells
Peiman Hematti, Christian M Capitini, Biotechnology Journal

Abstracts/Posters

The Potential of CAR T Therapy for Relapsed or Refractory Pediatric and Young Adult B-cell ALL
Christian Capitini, MD, Therapeutics and Clinical Risk Management, Orlando, FL, 12/7/2019

Other Languages

Spanish

External Links

Capitini Labhttps://www.pediatrics.wisc.edu/research/research-groups/capitini/